Analyzing Pacira BioSciences (NASDAQ:PCRX) & Allarity Therapeutics (NASDAQ:ALLR)

Pacira BioSciences (NASDAQ:PCRX) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.

Volatility and Risk

Pacira BioSciences has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Comparatively, Allarity Therapeutics has a beta of 0.08, indicating that its share price is 92% less volatile than the S&P 500.

Insider and Institutional Ownership

99.7% of Pacira BioSciences shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by company insiders. Comparatively, 0.1% of Allarity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Pacira BioSciences and Allarity Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pacira BioSciences	-18.08%	13.29%	6.61%
Allarity Therapeutics	N/A	-173.31%	-102.57%

Analyst Recommendations

This is a summary of current ratings and price targets for Pacira BioSciences and Allarity Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacira BioSciences	0	2	5	0	2.71
Allarity Therapeutics	0	0	1	0	3.00

Pacira BioSciences presently has a consensus target price of $30.8333, indicating a potential upside of 19.32%. Allarity Therapeutics has a consensus target price of $9.00, indicating a potential upside of 852.78%. Given Allarity Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Allarity Therapeutics is more favorable than Pacira BioSciences.

Earnings and Valuation

This table compares Pacira BioSciences and Allarity Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacira BioSciences	$700.97 million	1.66	-$99.56 million	($2.78)	-9.29
Allarity Therapeutics	N/A	N/A	-$24.51 million	N/A	N/A

Allarity Therapeutics has lower revenue, but higher earnings than Pacira BioSciences.

Summary

Pacira BioSciences beats Allarity Therapeutics on 7 of the 11 factors compared between the two stocks.

About Pacira BioSciences

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

About Allarity Therapeutics

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.